This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study. The goal of this Phase 2a study is to assess safety and efficacy of SAR442970 in comparison to placebo to preserve β-cell function in participants with recently diagnosed type 1 diabetes (T1D) on insulin therapy. The study …
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up …
This is a multicenter, single-arm, 24-week treatment, Phase 3 study. The purpose of this study is to investigate the PK and safety of dupilumab in children diagnosed with CSU who remain symptomatic despite the use of H1-antihistamine treatment. Study details include: Screening: 2 to 4 weeks; The treatment duration will …
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal …
The investigator's plan to determine whether pre-operative skin preparation with hydrogen peroxide alters rates of P acnes culture positivity. They hypothesize that pre-operative skin preparation with hydrogen peroxide will reduce rates of P acnes culture positivity.
Primary Objectives: To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. To evaluate the time-course of AD and selected atopic comorbidities. Secondary Objectives: To characterize disease burden and …
This is a prospective, 18-month observational study of adult, adolescent and pediatric Canadian participants with Atopic Dermatitis (AD) commonly known as Eczema, who receive treatment with Dupixent for moderate-to-severe AD (msAD) according to the Canadian-specific prescribing information (in accordance with the Canadian Dupixent Product Monograph). The study will be conducted …
Le registre sur la maladie de Fabry est un programme international, multicentrique et strictement observationnel qui suit actuellement les résultats cliniques de routine pour les patients atteints de la maladie de Fabry, peu importe le statut thérapeutique. Aucune intervention expérimentale n’est effectuée; les patients inscrits au registre passent des évaluations …
Le registre sur la maladie de Gaucher de l’ICGG est un programme international, multicentrique et strictement observationnel qui suit actuellement les résultats cliniques de routine pour les patients atteints de la maladie de Gaucher, peu importe le statut thérapeutique. Aucune intervention expérimentale n’est effectuée; les patients inscrits au registre passent …
Le registre sur la mucopolysaccharidose 1 (MPS 1) est une base de données observationnelle active qui suit les résultats des patients atteints de MPS 1. Les données recueillies par le registre de la MPS 1 fourniront des informations pour mieux caractériser l’histoire naturelle et la progression de la MPS 1 ainsi que les réponses cliniques …
